Cellular Engineering & Therapy Division
Did you know that cells can be engineered to model disease, repair damaged tissues and become living medicines?
The IMCB Cellular Engineering & Therapy (CET) Division advances the science and technologies needed to understand, engineer and harness cells for human health. It aims to build human-relevant models of development and disease, uncover the mechanisms that govern cell identity and function, and translate these insights into regenerative, immune and cell-based therapies.
We are a multidisciplinary team of scientists, bioengineers and clinicians working at the forefront of stem cell biology, regenerative medicine, tissue engineering, organoid technology, translational omics and cellular immunotherapy. By combining cell-fate engineering, advanced disease models and molecular profiling with preclinical and clinical expertise, we seek to develop more predictive research platforms and new therapeutic approaches.
Our team develops human pluripotent stem cell-derived cells, organoids and assembloids to study development and disease, regenerate complex tissues and advance cell replacement therapies. These capabilities span pancreatic, retinal, kidney, neural and epithelial systems, supported by biomaterials, scaffolds and translational disease models.
We investigate how genetic, epigenetic and environmental programmes shape cell identity and function. Single-cell and multi-omics technologies, proteomics, genome and epitranscriptome engineering, and patient-derived models enable us to uncover disease mechanisms and identify new therapeutic targets.
We study antigen presentation, immune regulation, and T- and NK-cell biology to develop next-generation cellular immunotherapies. Our work includes immune profiling, target and receptor discovery, and the engineering of CAR-T, TCR-T and other cell-based therapeutic platforms.
